Paradigm Medical Communications

Psoriasis Newsfeed

Psoriasis health indicator report

September 23, 2024

Gondo GC, Eakin G, Van Voorhees A, et al. Psoriasis health indicator report. National Psoriasis Foundation. Published January 2024.

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

June 30, 2024

Korman NJ, Warren RB, Bagel J, et al. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. 2024;35(1):2371045.

Association between cardio‐cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population‐based data: A nested case–control study

July 30, 2023

Kim BR, Lee KH, Kim J, et al. Association between cardio-cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population-based data: A nested case-control study [published online ahead of print, 2023 Jul 30]. J Dermatol. 2023;10.1111/1346-8138.16904. doi:10.1111/1346-8138.16904

Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention

August 9, 2023

Eder L, Lee KA, Chandran V, et al. Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention [published online ahead of print, 2023 Aug 9]. Arthritis Rheumatol. 2023;10.1002/art.42661. doi:10.1002/art.42661

The Figuring Out Psoriatic Disease CE Learning Center is an educational resource developed by Paradigm Medical Communications in collaboration with GRAPPA. The Learning Center, which features multiple individually accredited CME activities and patient and clinician resources, is for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.

For questions or technical support please email us at contactus@paradigmmc.com.